Various studies demonstrated that PARP inhibitors had promising results in clinical trials for BRCA1/2-mutant tumors, such as breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer [12–16]. This evidence concerns the gene BRCA1 and breast carcinoma.